By Jamie Lacey-Moreira – For the University of Maryland, Baltimore (UMB)
A company spun out of the University of Maryland School of Pharmacy aims to leverage its approach — combining modern artificial intelligence (AI) with traditional mechanistic models — to arm health care professionals with the best data to provide personalized treatment trajectories for patients.
Pumas-Al, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to Lyv, a clinical decision support system designed to help health care professionals personalize treatment options for patients in real-time.
“This could be a revolutionary new tool for health care providers, potentially informing real-time decisions about patient treatments,” said Phil Robilotto, DO, MBA, associate vice president of UMB’s Office of Technology Transfer and director of UM Ventures.
Products such as Lyv could help health care providers make faster and more informed decisions about patient care.
The Lyv platform leverages clinical research and electronic health record (EHR) data from millions of patients to derive algorithms that can personalize health care delivery. Lyv will have modules for anti-infectives, anti-epileptics, anti-coagulants, and anti-cancer that can be used in a hospital setting, and can also incorporate algorithms during new drug development. Such personalized treatment can help improve therapeutic success rates and minimize dosing errors.
Click here to read more via the Baltimore Business Journal